Clarus Therapeutics Holdings, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 555 Skokie Boulevard Northbrook IL United States of America 60062
- IPO Date
- Sep 7, 2021
- CIK
- 0001817944
- Website
- clarustherapeutics.com
- Similar Companies
- Business
- Clarus Therapeutics Holdings, Inc. is a pharmaceutical company engaged in the development and commercialization of androgen-based medicines, with a primary focus on oral testosterone replacement therapy for adult men with hypogonadism due to structural or genetic etiologies. The company offers JATENZO, a proprietary soft gel formulation of testosterone undecanoate linked with the fatty acid undecanoic acid; licensing agreements with HavaH Therapeutics for androgen therapies targeting inflammatory breast disease and certain breast cancers and with The Royal Institution for the Advancement of Learning/McGill University for proprietary technology addressing CoQ10 deficiency-related conditions including mitochondrial diseases. Founded in 2003 and headquartered in Northbrook, Illinois, Clarus Therapeutics Holdings operates in the United States through its subsidiary Clarus Therapeutics, Inc., targeting hypogonadal men and exploring metabolic therapies for men and women. In October 2022, the company sold its JATENZO assets to Tolmar Pharmaceuticals through a court-supervised auction amid financial challenges; its Chapter 11 plan of liquidation became effective on February 28, 2023, resulting in the cancellation of all interests, dissolution of the board, and deregistration of securities, with no distributions to stakeholders.
Clarus Therapeutics (CRXT) Stock: Why It Fell 31.16%
These Are The Five Best And Worst Performing Penny Stocks Of 2022 (So Far)
Clarus Therapeutics (CRXT) Stock Plunges Ahead of Aug. 31 Delisting
Top Penny Stocks To Buy? 4 For Your Watch List Before Next Week
Top Tricks for Trading Penny Stocks Right Now, 3 Tips
Hot Penny Stocks to Buy This Week? 3 to Watch Right Now
Hot Penny Stocks to Buy in July? Check These 3 Out
Clarus Therapeutics Holdings, Inc. (CRXT) CEO Bob Dudley on Q1 2022 Results - Earnings Call Transcript
Hot Penny Stocks You Need to Know About This Month
Hot Penny Stocks To Buy For Under $1 This Week
Insiders Are Dumping These Penny Stocks, Look Out Below Or Buy The Dip?
Why Clarus Therapeutics Shares Are Getting Hammered
3 Hot Penny Stocks to Add to Your Small-Caps Watch List This Week
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen Society 4th Annual Meeting
Best Penny Stocks to Buy? 3 to Watch as Musk Offers $43B for TWTR
Clarus Therapeutics Holdings' (CRXT) CEO Bob Dudley on Q4 2021 Results - Earnings Call Transcript
Clarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Results
3 Hot Meme Penny Stocks to Watch Under $3 Right Now
Best Reddit Penny Stocks to Watch During Trading Today
4 Trending Penny Stocks to Add to Your Watchlist Right Now